Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H14ClNO |
| Molecular Weight | 223.699 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1(CCCCC1=O)C2=C(Cl)C=CC=C2
InChI
InChIKey=BEQZHFIKTBVCAU-UHFFFAOYSA-N
InChI=1S/C12H14ClNO/c13-10-6-2-1-5-9(10)12(14)8-4-3-7-11(12)15/h1-2,5-6H,3-4,7-8,14H2
| Molecular Formula | C12H14ClNO |
| Molecular Weight | 223.699 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Norketamine is one of the major metabolites of Ketamine, which is routinely used as an anesthetic. Norketamine is a potent antagonist of the N-methyl-D-aspartate receptor and is believed to contribute to the analgesic effects of ketamine. In animal models, norketamine has been noted to increase the glomerular filtration rate by remodeling the cellular cytoskeleton, and it has been identified as having possible antidepressant effects.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics and analgesic effects of i.m. and oral ketamine. | 1981 Aug |
|
| Family history of cancer and mortality among patients gastrectomized because of benign gastric diseases. | 1990 Jul |
|
| Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. | 1997 Aug 20 |
|
| Interaction between morphine and norketamine enantiomers in rodent models of nociception. | 2008 Oct |
|
| Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. | 2009 Sep |
|
| (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. | 2014 Jul |
|
| Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. | 2015 Dec |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: It should be noted that this dosage is approximately 20 times less than the metabolic dose when ketamine is administered as an anesthetic. https://www.ncbi.nlm.nih.gov/pubmed/17439422
Balb/c mice were treated with norketamine for 3 days at a dose of 0.3 mg/100g delivered by intraperitoneal injection. Urinary excretion of albumin and creatine were both increased over the next 24 hours.
Route of Administration:
Intraperitoneal
Podocyte cells were cultured and extracted from rat Kidneys. Cells were cultured for 1 week with collagen type IV at 37°C in 5% CO2 atmosphere. An NMDA receptor blockade was established by adding 50 microM of Norketamine Hydrochloride to the cell media. After 30 minutes a profound remodeling of podocyte cytoskeleton was observed, highlighted by the disappearance of actin stress fibers and redistribution of myosin-IIA. When the same concentration of norketamine was added to isolated rat glomeruli there was a significant increase in glomerular albumin permeability.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:20:16 GMT 2023
by
admin
on
Sat Dec 16 11:20:16 GMT 2023
|
| Record UNII |
XQY6JVF94X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65329-10-4
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
SUPERSEDED | |||
|
35211-10-0
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY | |||
|
DTXSID40891434
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY | |||
|
123767
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY | |||
|
NORKETAMINE
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY | |||
|
100000176238
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY | |||
|
XQY6JVF94X
Created by
admin on Sat Dec 16 11:20:16 GMT 2023 , Edited by admin on Sat Dec 16 11:20:16 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
|
||
|
BINDER->LIGAND |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
|
